ArticleEuropean journal of cancer (Oxford, England : 1990)2010
Autoantibody profiling to identify biomarkers of key pathogenic pathways in mucinous ovarian cancer.
Article in European journal of cancer (Oxford, England : 1990), 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 33 citations in OpenAlex.
- Review
- Circulating Tumor Cells Enumerated by a Centrifugal Microfluidic Device as a Predictive Marker for Monitoring Ovarian Cancer Treatment: A Pilot Study.Diagnostics (Basel, Switzerland) · 2020Article
- Increased expression of NaOncology letters · 2018Article
- The role of biomarkers in the management of epithelial ovarian cancer.Expert review of molecular diagnostics · 2017Review
- C-terminal binding protein-2 promotes cell proliferation and migration in breast cancer via suppression of p16INK4A.Oncotarget · 2017Article
- A systems medicine approach for finding target proteins affecting treatment outcomes in patients with non-Hodgkin lymphoma.PloS one · 2017Article
- Developmental signaling pathways regulating mammary stem cells and contributing to the etiology of triple-negative breast cancer.Breast cancer research and treatment · 2016Review
- Pinin interacts with C-terminal binding proteins for RNA alternative splicing and epithelial cell identity of human ovarian cancer cells.Oncotarget · 2016Article
- Autoantibody Profiling of Glioma Serum Samples to Identify Biomarkers Using Human Proteome Arrays.Scientific reports · 2015Article
- Interaction with CCNH/CDK7 facilitates CtBP2 promoting esophageal squamous cell carcinoma (ESCC) metastasis via upregulating epithelial-mesenchymal transition (EMT) progression.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2015Article
- Rac1 expression in epithelial ovarian cancer: effect on cell EMT and clinical outcome.Medical oncology (Northwood, London, England) · 2015Article
- Autoantibody signature for the serologic detection of ovarian cancer.Journal of proteome research · 2015Article
- High expression and prognostic role of CAP1 and CtBP2 in breast carcinoma: associated with E-cadherin and cell proliferation.Medical oncology (Northwood, London, England) · 2014Article
- Prognostic value of centromere protein-A expression in patients with epithelial ovarian cancer.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2013Article
- C-terminal binding protein-2 regulates response of epithelial ovarian cancer cells to histone deacetylase inhibitors.Oncogene · 2013Article
- BRCA1 expression is epigenetically repressed in sporadic ovarian cancer cells by overexpression of C-terminal binding protein 2.Neoplasia (New York, N.Y.) · 2013Article
- High-throughput screening for native autoantigen-autoantibody complexes using antibody microarrays.Journal of proteome research · 2013Article
- Interaction with cyclin H/cyclin-dependent kinase 7 (CCNH/CDK7) stabilizes C-terminal binding protein 2 (CtBP2) and promotes cancer cell migration.The Journal of biological chemistry · 2013Article
- Article
- Casein kinase I epsilon interacts with mitochondrial proteins for the growth and survival of human ovarian cancer cells.EMBO molecular medicine · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 4 institutions in 3 countries.
Funding
Abstract
Mucinous epithelial ovarian cancers are clinically and morphologically distinct from the other histopathologic subtypes of ovarian cancer. Unlike other ovarian subtypes, epidemiologic studies have indicated that tobacco exposure is a significant risk factor for developing mucinous ovarian cancer. Detection of autoantibody reactivity is useful in biomarker discovery and for explaining the role of important pathophysiologic pathways in disease. In order to study if there are specific antibody biomarkers in the plasma samples of mucinous ovarian cancer patients, we have initiated a screen by employing a 'reverse capture antibody microarray' platform that uses native host antigens derived from mucinous ovarian tissues as 'baits' for the capture of differentially labelled patient and control autoantibodies. Thirty-five autoantibodies that were significantly elevated in the cancer plasma samples compared with healthy controls, and six autoantibodies that segregated smoking and non-smoking patients were identified. Functional annotation of the antibody targets has identified nine target antigens involved in integrin and Wnt signalling pathways. Immunohistochemistry of archived ovarian specimens showed significant overexpression of eight of the nine target antigens in mucinous ovarian tumour tissues, suggesting that plasma autoantibodies from mucinous ovarian cancer patients might have heightened reactivities with epitopes presented by these overexpressed antigens. Autoantibody profiling may have an unexpected utility in uncovering key signalling pathways that are dysregulated in the system of interest.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.